Genmab A/S
GMAB33.420USD
-0.300-0.89%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
20.58BMarket Cap
14.14P/E TTM
More Details of Genmab A/S Company
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.
Genmab A/S Info
Ticker SymbolGMAB
Company nameGenmab A/S
IPO dateOct 01, 2000
CEOVan De Winkel (Jan G.J)
Number of employees2682
Security typeDepository Receipt
Fiscal year-endOct 01
AddressCarl Jacobsens Vej 30
CityVALBY
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryDenmark
Postal code2500
Phone4570202728
Websitehttps://www.genmab.com/
Ticker SymbolGMAB
IPO dateOct 01, 2000
CEOVan De Winkel (Jan G.J)
Company Executives of Genmab A/S
Name
Name/Position
Position
Shareholding
Change
Dr. Tahamtan (Tahi) Ahmadi, M.D., Ph.D.
Dr. Tahamtan (Tahi) Ahmadi, M.D., Ph.D.
Executive Vice President, Chief Medical Officer, Head of Experimental Medicines
Executive Vice President, Chief Medical Officer, Head of Experimental Medicines
--
--
Dr. Judith V. Klimovsky, M.D.
Dr. Judith V. Klimovsky, M.D.
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
--
--
Ms. Pernille Lyngvold Erenbjerg
Ms. Pernille Lyngvold Erenbjerg
Independent Deputy Chairman of the Board
Independent Deputy Chairman of the Board
--
--
Mr. Christopher Cozic
Mr. Christopher Cozic
Executive Vice President, Chief People Officer
Executive Vice President, Chief People Officer
--
--
Mr. Martin Schultz
Mr. Martin Schultz
Non-Independent Director, Employee Elected
Non-Independent Director, Employee Elected
--
--
Dr. Anders Gersel Pedersen, M.D., Ph.D.
Dr. Anders Gersel Pedersen, M.D., Ph.D.
Non-Independent Director
Non-Independent Director
--
--
Dr. Paolo Paoletti, M.D.
Dr. Paolo Paoletti, M.D.
Independent Director
Independent Director
--
--
Dr. Jan G.J. Van De Winkel, Ph.D.
Dr. Jan G.J. Van De Winkel, Ph.D.
President, Chief Executive Officer
President, Chief Executive Officer
--
--
Ms. Mijke Zachariasse, Ph.D.
Ms. Mijke Zachariasse, Ph.D.
Non-Independent Director, Employee Elected
Non-Independent Director, Employee Elected
--
--
Ms. Elizabeth A. O'farrell
Ms. Elizabeth A. O'farrell
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Tahamtan (Tahi) Ahmadi, M.D., Ph.D.
Dr. Tahamtan (Tahi) Ahmadi, M.D., Ph.D.
Executive Vice President, Chief Medical Officer, Head of Experimental Medicines
Executive Vice President, Chief Medical Officer, Head of Experimental Medicines
--
--
Dr. Judith V. Klimovsky, M.D.
Dr. Judith V. Klimovsky, M.D.
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
--
--
Ms. Pernille Lyngvold Erenbjerg
Ms. Pernille Lyngvold Erenbjerg
Independent Deputy Chairman of the Board
Independent Deputy Chairman of the Board
--
--
Mr. Christopher Cozic
Mr. Christopher Cozic
Executive Vice President, Chief People Officer
Executive Vice President, Chief People Officer
--
--
Mr. Martin Schultz
Mr. Martin Schultz
Non-Independent Director, Employee Elected
Non-Independent Director, Employee Elected
--
--
Dr. Anders Gersel Pedersen, M.D., Ph.D.
Dr. Anders Gersel Pedersen, M.D., Ph.D.
Non-Independent Director
Non-Independent Director
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Royalties
789.00M
85.30%
Net product sales
101.00M
10.92%
Collaboration revenue
21.00M
2.27%
Reimbursement income
13.00M
1.41%
Milestone payments
1.00M
0.11%
Relevant data have not been disclosed by the company yet.
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Royalties
789.00M
85.30%
Net product sales
101.00M
10.92%
Collaboration revenue
21.00M
2.27%
Reimbursement income
13.00M
1.41%
Milestone payments
1.00M
0.11%
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Orbis Investment Management Ltd.
1.80%
AllianceBernstein L.P.
1.78%
Paradigm BioCapital Advisors LP
0.62%
Arrowstreet Capital, Limited Partnership
0.59%
Harding Loevner LP
0.57%
Other
94.64%
Shareholders
Shareholders
Proportion
Orbis Investment Management Ltd.
1.80%
AllianceBernstein L.P.
1.78%
Paradigm BioCapital Advisors LP
0.62%
Arrowstreet Capital, Limited Partnership
0.59%
Harding Loevner LP
0.57%
Other
94.64%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
4.59%
Investment Advisor
3.46%
Hedge Fund
1.96%
Research Firm
0.19%
Pension Fund
0.03%
Bank and Trust
0.02%
Family Office
0.01%
Venture Capital
0.01%
Other
89.71%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
515
64.81M
10.54%
-15.68M
2025Q2
501
65.30M
10.31%
-6.21M
2025Q1
515
65.99M
10.42%
-5.32M
2024Q4
512
61.76M
9.33%
+621.44K
2024Q3
493
53.46M
8.41%
-4.14M
2024Q2
495
49.90M
7.86%
-6.30M
2024Q1
501
49.04M
7.53%
-7.16M
2023Q4
490
47.86M
7.32%
-6.37M
2023Q3
479
48.54M
7.43%
+204.98K
2023Q2
467
42.76M
6.55%
-5.77M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Orbis Investment Management Ltd.
7.92M
1.29%
+2.21M
+38.69%
Jun 30, 2025
AllianceBernstein L.P.
10.66M
1.73%
-4.06M
-27.59%
Jun 30, 2025
Arrowstreet Capital, Limited Partnership
3.45M
0.56%
+2.08M
+152.25%
Jun 30, 2025
Harding Loevner LP
2.92M
0.48%
+42.61K
+1.48%
Jun 30, 2025
Two Sigma Investments, LP
3.44M
0.56%
-433.92K
-11.20%
Jun 30, 2025
Renaissance Technologies LLC
2.77M
0.45%
+504.40K
+22.30%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
2.50M
0.41%
-443.29K
-15.04%
Jun 30, 2025
First Trust Advisors L.P.
1.77M
0.29%
+60.50K
+3.54%
Jun 30, 2025
Parametric Portfolio Associates LLC
1.19M
0.19%
-6.41K
-0.54%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Tema Oncology ETF
4.2%
First Trust NYSE Arca Biotechnology Index Fund
3.02%
WisdomTree BioRevolution Fund
1.31%
iShares Biotechnology ETF
1.15%
AB Disruptors ETF
0.69%
JPMorgan Healthcare Leaders ETF
0.28%
First Trust NASDAQ BuyWrite Income ETF
0.26%
ProShares Ultra Nasdaq Biotechnology
0.12%
Invesco Nasdaq Biotechnology ETF
0.12%
ActivePassive International Equity ETF
0.12%
View more
Tema Oncology ETF
Proportion4.2%
First Trust NYSE Arca Biotechnology Index Fund
Proportion3.02%
WisdomTree BioRevolution Fund
Proportion1.31%
iShares Biotechnology ETF
Proportion1.15%
AB Disruptors ETF
Proportion0.69%
JPMorgan Healthcare Leaders ETF
Proportion0.28%
First Trust NASDAQ BuyWrite Income ETF
Proportion0.26%
ProShares Ultra Nasdaq Biotechnology
Proportion0.12%
Invesco Nasdaq Biotechnology ETF
Proportion0.12%
ActivePassive International Equity ETF
Proportion0.12%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Genmab A/S?
The top five shareholders of Genmab A/S are:
Orbis Investment Management Ltd. holds 7.92M shares, accounting for 1.29% of the total shares.
AllianceBernstein L.P. holds 10.66M shares, accounting for 1.73% of the total shares.
Arrowstreet Capital, Limited Partnership holds 3.45M shares, accounting for 0.56% of the total shares.
Harding Loevner LP holds 2.92M shares, accounting for 0.48% of the total shares.
Two Sigma Investments, LP holds 3.44M shares, accounting for 0.56% of the total shares.
Orbis Investment Management Ltd. holds 7.92M shares, accounting for 1.29% of the total shares.
AllianceBernstein L.P. holds 10.66M shares, accounting for 1.73% of the total shares.
Arrowstreet Capital, Limited Partnership holds 3.45M shares, accounting for 0.56% of the total shares.
Harding Loevner LP holds 2.92M shares, accounting for 0.48% of the total shares.
Two Sigma Investments, LP holds 3.44M shares, accounting for 0.56% of the total shares.
What are the top three shareholder types of Genmab A/S?
The top three shareholder types of Genmab A/S are:
Orbis Investment Management Ltd.
AllianceBernstein L.P.
Paradigm BioCapital Advisors LP
Orbis Investment Management Ltd.
AllianceBernstein L.P.
Paradigm BioCapital Advisors LP
How many institutions hold shares of Genmab A/S (GMAB)?
As of 2025Q3, 515 institutions hold shares of Genmab A/S, with a combined market value of approximately 64.81M, accounting for 10.54% of the total shares. Compared to 2025Q2, institutional shareholding has increased by 0.23%.
What is the biggest source of revenue for Genmab A/S?
In FY2025Q2, the Royalties business generated the highest revenue for Genmab A/S, amounting to 789.00M and accounting for 85.30% of total revenue.
